Elsevier

Cytokine

Volume 66, Issue 1, March 2014, Pages 40-45
Cytokine

Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension

https://doi.org/10.1016/j.cyto.2013.12.013Get rights and content

Highlights

  • Inflammation is involved in the pathogenesis of pulmonary arterial hypertension (PAH).

  • PAH patients present elevated sCD163 and lower serum sTWEAK levels than controls.

  • The sTWEAK/sCD163 ratio appears to be a better indicator of the severity of PAH than either marker alone.

  • The exact role of sCD163 or CD163–sTWEAK interaction in PAH remains to be established.

Abstract

Background

Inflammation may play a pivotal role in the pathogenesis of pulmonary arterial hypertension (PAH). We evaluated the concentrations of serum sTWEAK, its scavenger receptor sCD163 and sTWEAK/sCD163 ratio in patients with PAH.

Design

The study enrolled 26 stable patients with PAH confirmed by right heart catheterization and 24 healthy volunteers matched for age, sex and body weight. All patients underwent transthoracic echocardiography, cardiopulmonary exercise test, 6-min walk test, measurement of lung diffusing capacity for the carbon monoxide (DLCO) and venous blood tests. Concentrations of sTWEAK and sCD163 were determined using ELISA kits.

Results

The PAH patients were characterized by significantly higher median serum sCD163 levels (1072 vs 890 ng/ml, p = 0.04) together with lower serum sTWEAK concentrations (200 vs 278.1 pg/ml, p = 0.003) comparing to control subjects. sTWEAK/sCD163 ratio was therefore significantly lower in PAH group (0.18 vs 0.33, p = 0.0005). No correlation was found between sTWEAK and sCD163 concentrations in both groups. We observed statistically significant inverse correlation between peak VO2 consumption and sCD163 concentrations (r = −0.52, p < 0.05) and positive with sTWEAK/sCD163 ratio (r = 0.45, p < 0.05) in PAH group. Moreover, sTWEAK/sCD163 ratio positively correlated with % of predicted values of DLCO (r = 0.42, p < 0.05).

Conclusions

Patients with PAH present altered serum sTWEAK and sCD163 levels. The sTWEAK/sCD163 ratio appears to be a better indicator of the severity of PAH as compared to sTWEAK or sCD163 alone. The exact role of sCD163 or interaction between CD163 and sTWEAK in the initiation or progression of PAH as well as their potential prognostic significance remains to be established.

Introduction

Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by fibrotic and proliferative changes in small pulmonary arteries that produce a gradual increase in pulmonary vascular resistance and lead to right-heart failure and premature death. It has been widely described that of the multiple and complex mechanisms contributing to PAH development, endothelial injury, chronic inflammatory state and increased vascular cells proliferation are the major ones involved in the pulmonary vascular remodelling [1].

CD163 is a scavenger receptor exclusively expressed by monocytes and macrophages. It is considered a marker of macrophage population of anti-inflammatory activity. Macrophages are a heterogeneous group of cells activated by various stimuli that can differentiate toward a M1 or a M2 phenotype. The M1 subpopulation produce nitrogen intermediates and pro-inflammatory mediators that promote inflammatory responses. In contrast, the M2 subpopulation secretes predominantly anti-inflammatory cytokines and is also associated with vascularization and tissue repair [2]. Several specific surface receptors are expressed by M2 cells and CD163 scavenger receptor is one of them. It is involved in the clearance of hemoglobin–haptoglobin (Hb–Hp) complexes, protecting tissues from oxidative damage and inflammation [3]. CD163 expression is up-regulated during resolution phase of acute inflammatory response and also in chronic inflammatory diseases possibly reflecting counter-regulatory, adaptation, homeostatic mechanisms. The soluble form (sCD163) is released from the cell surface by proteolysis. The enzymes involved in this process are activated by pro-inflammatory mediators leading to elevated levels of sCD163 in peripheral blood and other tissue fluids during inflammatory diseases. Therefore sCD163 can be considered as a potential biomarker of inflammatory condition, e.g. in autoimmune diseases, asthma or atherosclerosis [4], [5], [6], [7]. Recent studies have revealed that CD163 can also bind soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) [8], which is an inflammatory cytokine belonging to the tumor necrosis factor-alpha (TNF-alpha) superfamily. It modulates multiple biological responses associated with tissue damage and repair, such as proliferation, differentiation, inflammation, apoptosis and angiogenesis [9]. It acts mainly via binding to the fibroblast growth factor-inducible 14 receptor (Fn14), which is rarely expressed on macrophage surface, making CD163 a specific receptor for sTWEAK on monocytes/macrophages [8], [9]. Binding sTWEAK by CD163 leads to neutralization of both molecules, for that reason CD163 seems to act as a “decoy” receptor for sTWEAK [8]. The interaction of sTWEAK with CD163 might be the mechanism that balances inflammatory reactions. Therefore we assume that sTWEAK/sCD163 ratio will better reflect biological activity of sTWEAK.

Recent studies have demonstrated a potential role of sTWEAK in pathogenesis of atherosclerosis as well as prognostic value of this cytokine in chronic heart failure and myocardial infarction [10], [11], [12], [13]. TWEAK/Fn14 pathway plays an important role in regulation of cardiac, and particularly right ventricular, hypertrophy and fibrosis [10], [12]. There is a growing evidence suggesting that sTWEAK may contribute to the pathogenesis of PAH and also have predictive significance [14]. Moreover, these two phenomena very well fit together, as right ventricular function is a major determinant of prognosis in pulmonary arterial hypertension [1].

In this context, the current study aimed at assessment of alterations in the levels of sCD163 and sTWEAK in patients with PAH as potential factors involved in the pathobiology of this disease.

Section snippets

Population

This single-center study included 26 patients with pulmonary arterial hypertension. These subjects made a complete population of PAH patients in north-eastern Poland. The diagnosis of PAH was based on established criteria [1] and confirmed by right-sided heart catheterization, using standard hemodynamic measurements: mean pulmonary artery pressure (mPAP), pulmonary capillary wedge pressure (PCWP), cardiac output (CO) and cardiac index (CI). The reference cohort consisted of 24 healthy

Results

The study enrolled 26 stable patients with confirmed diagnosis of PAH, in II–IV WHO functional class and 24 healthy volunteers matched for age, sex and body weight. They were patients with idiopathic PAH (46.2%, n = 12) as well as with PAH associated with connective tissue diseases and congenital heart diseases (26.9%, n = 7 both groups). Of these, 61.5% (n = 16) were prevalent cases, the rest (38.5%, n = 10) were incident cases. Mean age in the study group was 51.1 (±17.8) years vs 47.2 (±13.6) years

Discussion

This is the first study, to our knowledge, that reports significantly elevated serum levels of scavenger receptor, soluble CD163, in patients with PAH. Moreover, we demonstrated for the first time decreased sTWEAK/sCD163 ratio in this group of patients compared to healthy controls.

Numerous studies have documented that patients with idiopathic PAH exhibit higher plasma levels or pulmonary expression of proinflammatory cytokines and chemokines such as IL-1β, IL-6, TNF-alpha, fractalkine and

Conclusions

Patients with PAH present altered serum sTWEAK and sCD163 levels. The sTWEAK/sCD163 ratio appears to be a better indicator of the severity of PAH as compared to sTWEAK or sCD163 alone. The exact role of sCD163 or interaction between CD163 and sTWEAK in the initiation or progression of PAH as well as their potential prognostic significance remains to be established.

Contributions

Malgorzata Jasiewicz: designed and performed research, collected and analyzed data, wrote paper.

Krzysztof Kowal: performed research, collected data, wrote paper.

Otylia Kowal-Bielecka: performed research, wrote paper.

Malgorzata Knapp: performed research, collected data.

Roman Skiepko: performed research, collected data.

Anna Bodzenta-Lukaszyk: analyzed data.

Bozena Sobkowicz: performed research.

Wlodzimierz Jerzy Musial: analyzed data.

Karol Adam Kaminski: designed research, analyzed data, wrote

Acknowledgements

The research was supported by National Science Centre Grant (2011/01/N/NZ5/04361) and statutory activity of Medical University of Bialystok (113-53832L).

References (28)

  • N. Galiè et al.

    Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

    Eur Heart J

    (2009)
  • S. Yona et al.

    Monocytes: subsets, origins, fates and functions

    Curr Opin Hematol

    (2010)
  • N. Matsushita et al.

    Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3

    Clin Exp Immunol

    (2002)
  • K. Kowal et al.

    Differential expression of monocyte CD163 in single- and dual-asthmatic responders during allergen-induced bronchoconstriction

    Clin Exp Allergy

    (2006)
  • Cited by (26)

    • The role of platelets in the development and progression of pulmonary arterial hypertension

      2018, Advances in Medical Sciences
      Citation Excerpt :

      Recent studies have confirmed the role of inflammatory modulators e.g. kynurenine metabolites, interleukin-6 and IL-1β, in the development of PAH [8–10]. Another one of them is the soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK), which belongs to the TNFα superfamily [7,11]. This cytokine is involved in numerous biological responses associated with tissue damage and repair, such as apoptosis, cell growth or angiogenesis [11].

    • The significance of diminished sTWEAK and P-selectin content in platelets of patients with pulmonary arterial hypertension

      2018, Cytokine
      Citation Excerpt :

      Possible effect of sTWEAK on compensated hypertrophy of right ventricle due to pulmonary hypertension still requires further research, however increasing body of evidence indicates that sTWEAK is involved in the pathogenesis of PAH. Our previous study reported that patients with PAH present altered serum sTWEAK and sCD163 levels as well as have decreased sTWEAK/sCD163 ratio, so the interaction between sTWEAK and its scavenger receptor CD163 could play an important role in maintaining inflammatory processes in this disease [4]. In this study we show that the plasma levels of sTWEAK are similar in both the PAH patients and the control subjects.

    • Role of TWEAK/Fn14 signalling pathway in lupus nephritis and other clinical settings

      2017, Nefrologia
      Citation Excerpt :

      It is striking that they found a directly proportional relationship between the levels of sTWEAK and MCP-1 and the Gensini score obtained. Jasiewicz et al.30 evaluated the relationship of TWEAK in other cardiovascular scenarios. This group performed a comparative study of 26 patients with pulmonary hypertension, confirmed by right heart catheterisation and 24 healthy volunteers.

    • The strengths and weaknesses of non-invasive parameters obtained by echocardiography and cardiopulmonary exercise testing in comparison with the hemodynamic assessment by the right heart catheterization in patients with pulmonary hypertension

      2017, Advances in Medical Sciences
      Citation Excerpt :

      Pulmonary hypertension (PH) may complicate the course of many cardiac and non-cardiac diseases or can be idiopathic or familial [1–3].

    • Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure

      2016, Cytokine
      Citation Excerpt :

      In our study sCD163 was associated with chronic comorbidities such as arterial hypertension. Similar suggestion of the role of this receptor was given previously in the analysis of patients with right heart failure in the course of pulmonary hypertension [26]. This observation is underlined by knowledge, that macrophages play an important role in mediation of chronic inflammatory activation in heart failure and soluble form of CD163 reflects the total amount of the receptor expressed on monocytes/macrophages [27,28].

    View all citing articles on Scopus
    View full text